{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T09:07:22Z","timestamp":1791018442593,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.eclinm.2025.103378","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T11:34:48Z","timestamp":1753184088000},"page":"103378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Therapeutic anti-cancer vaccines: a systematic review of prospective intervention trials for common hematological malignancies"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6784-0058","authenticated-orcid":false,"given":"Darshi","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6337-9455","authenticated-orcid":false,"given":"Veer","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prachi J.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muatassem","family":"Alsadhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson","family":"Haslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzaffar H.","family":"Qazilbash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajshekhar","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6464-783X","authenticated-orcid":false,"given":"Ghulam Rehman","family":"Mohyuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.eclinm.2025.103378_bib1","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103378_bib2","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ajh.26822","article-title":"Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Shimony","year":"2023","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103378_bib3","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103378_bib4","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1200\/JCO.22.01848","article-title":"Navigating the evolving treatment landscape of diffuse large B-cell lymphoma","volume":"41","author":"Nastoupil","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103378_bib5","article-title":"Recent advances in cancer immunotherapy with a focus on FDA-approved vaccines and neoantigen-based vaccines","volume":"11","author":"Hargrave","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103378_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-022-00257-2","article-title":"Research progress on dendritic cell vaccines in cancer immunotherapy","volume":"11","author":"Yu","year":"2022","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103378_bib7","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1182\/hematology.2019000068","article-title":"Myeloma: next generation immunotherapy","volume":"2019","author":"Cohen","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103378_bib8","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s43018-022-00418-6","article-title":"Cancer vaccines: the next immunotherapy frontier","volume":"3","author":"Lin","year":"2022","journal-title":"Nat Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103378_bib9","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges, and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103378_bib10","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.blre.2018.02.002","article-title":"Anti-cancer vaccine therapy for hematologic malignancies: an evolving era","volume":"32","author":"Nahas","year":"2018","journal-title":"Blood Rev"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103378_bib11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eclinm.2025.103378_bib12","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.2","year":"2021"},{"key":"10.1016\/j.eclinm.2025.103378_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103378_bib14","first-page":"88","article-title":"[The efficacy of active specific immunotherapy using modified neoplastic cells in the combined modality treatment of hemoblastoses]","author":"Zverkova","year":"1998","journal-title":"Lik Sprava"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103378_bib16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/1097-0142(19800701)46:1<22::AID-CNCR2820460104>3.0.CO;2-P","article-title":"Remission maintenance for acute nonlymphocytic leukemia: cytosine arabinoside plus 6-thioguanine versus a sequence of drug regimens","volume":"46","author":"Presant","year":"1980","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103378_bib17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/14796694.2024.2433935","article-title":"REGAL: galinpepimut-S vs. best available therapy as maintenance therapy for acute myeloid leukemia in second remission","volume":"21","author":"Jamy","year":"2025","journal-title":"Future Oncol"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103378_bib18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/bjc.1973.162","article-title":"Immunotherapy for acute myelogenous leukaemia","volume":"28","author":"Powles","year":"1973","journal-title":"Br J Cancer"},{"issue":"49","key":"10.1016\/j.eclinm.2025.103378_bib19","first-page":"3637","article-title":"[Prolonged survival in adults with acute myeloid leukemia treated with BCG immunotherapy]","volume":"11","author":"Vu Van","year":"1982","journal-title":"Nouv Presse Med"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103378_bib20","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/bjc.1980.60","article-title":"Immunotherapy alone vs no maintenance treatment in acute myelogenous leukaemia","volume":"41","author":"Zuhrie","year":"1980","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103378_bib21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF00205783","article-title":"A randomized clinical trial of remission induction, consolidation, and chemo-immunotherapy maintenance in adult acute myeloblastic leukemia","volume":"3","author":"Vogler","year":"1978","journal-title":"Cancer Immunol Immunother"},{"issue":"8048","key":"10.1016\/j.eclinm.2025.103378_bib22","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(77)90549-9","article-title":"Maintenance of remission in acute myelogenous leukaemia by a mixture of B.C.G. and irradiated leukaemia cells","volume":"2","author":"Powles","year":"1977","journal-title":"Lancet"},{"issue":"7873","key":"10.1016\/j.eclinm.2025.103378_bib23","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S0140-6736(74)91556-6","article-title":"Prolonging remission in myeloblastic leuk\u00e6mia by tice-strain Bacillus Calmette-Gu\u00e9rin","volume":"304","author":"Vogler","year":"1974","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2025.103378_bib24","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1182\/blood-2022-162169","article-title":"Use of an allogeneic leukemia-derived dendritic cell vaccine in MRD+ AML-patients results in MRD conversion, improved relapse-free survival and vaccine induced immune responses to tumor antigens","volume":"140","author":"Loosdrecht","year":"2022","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.eclinm.2025.103378_bib25","doi-asserted-by":"crossref","first-page":"6696","DOI":"10.1158\/1078-0432.CCR-21-1916","article-title":"An allogeneic multiple myeloma GM-CSF-secreting vaccine with lenalidomide induces long-term immunity and durable clinical responses in patients in near complete remission","volume":"27","author":"Biavati","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103378_bib26","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/ejh.13982","article-title":"PD-L1 expression predicts efficacy in the phase II SPiReL trial with MVP-S, pembrolizumab, and low-dose CPA in R\/R DLBCL","volume":"111","author":"Amitai","year":"2023","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103378_bib27","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/ajh.21560","article-title":"Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival","volume":"84","author":"Lacy","year":"2009","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103378_bib28","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/BF00205305","article-title":"Immunotherapy for remission maintenance in acute myeloblastic leukemia","volume":"13","author":"Baker","year":"1982","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103378_bib29","first-page":"197","article-title":"Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer","volume":"36","author":"Anassi","year":"2011","journal-title":"P T"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103378_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13061383","article-title":"Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma","volume":"13","author":"Ferrucci","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103378_bib31","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"issue":"23","key":"10.1016\/j.eclinm.2025.103378_bib32","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103378_bib33","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.mayocp.2015.05.006","article-title":"Hard-wired bias: how even double-blind, randomized controlled trials can Be skewed from the start","volume":"90","author":"Prasad","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.eclinm.2025.103378_bib34","first-page":"1539","article-title":"Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008","volume":"8","author":"Lu","year":"2014","journal-title":"Drug Des Devel Ther"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103378_bib35","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1182\/blood.2020008493","article-title":"A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma","volume":"139","author":"Qazilbash","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103378_bib36","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.drudis.2021.02.006","article-title":"Cancer vaccines: an unkept promise?","volume":"26","author":"Kamath","year":"2021","journal-title":"Drug Discov Today"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103378_bib37","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","article-title":"Challenges in developing personalized neoantigen cancer vaccines","volume":"24","author":"Katsikis","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.eclinm.2025.103378_bib38","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2018.12.011","article-title":"Neoepitopes-based vaccines: challenges and perspectives","volume":"108","author":"Alcazer","year":"2019","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103378_bib39","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/imm.13233","article-title":"Generation of multiepitope cancer vaccines based on large combinatorial libraries of survivin-derived mutant epitopes","volume":"161","author":"Dominguez-Romero","year":"2020","journal-title":"Immunology"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103378_bib40","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41568-025-00820-z","article-title":"Recent advances in therapeutic cancer vaccines","volume":"25","author":"Zaidi","year":"2025","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103378_bib41","article-title":"Selecting target antigens for cancer vaccine development","volume":"8","author":"Buonaguro","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103378_bib42","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1158\/1078-0432.CCR-20-0245","article-title":"The changing landscape of therapeutic cancer vaccines-novel platforms and neoantigen identification","volume":"27","author":"Jou","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eclinm.2025.103378_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1050484","article-title":"The effects of dendritic cell-based vaccines in the tumor microenvironment: impact on myeloid-derived suppressor cells","volume":"13","author":"Sanchez-Leon","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.eclinm.2025.103378_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1129343","article-title":"Modulation of T-cell function by myeloid-derived suppressor cells in hematological malignancies","volume":"11","author":"Bhardwaj","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.eclinm.2025.103378_bib45","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.3389\/fimmu.2018.02264","article-title":"Novel strategies for peptide-based vaccines in hematological malignancies","volume":"9","author":"Klausen","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.eclinm.2025.103378_bib46","article-title":"Peptide-based vaccine for cancer therapies","volume":"14","author":"Buonaguro","year":"2023","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103378_bib47","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1080\/14712598.2016.1190828","article-title":"Challenges in vaccine therapy in hematological malignancies and strategies to overcome them","volume":"16","author":"Nahas","year":"2016","journal-title":"Expert Opin Biol Ther"},{"issue":"20","key":"10.1016\/j.eclinm.2025.103378_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252011256","article-title":"Cancer vaccines: recent insights and future directions","volume":"25","author":"Malacopol","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"17","key":"10.1016\/j.eclinm.2025.103378_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/cells12172159","article-title":"Cancer vaccine therapeutics: limitations and effectiveness-A literature review","volume":"12","author":"Kaczmarek","year":"2023","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103378_bib50","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nri.2017.131","article-title":"Towards personalized, tumour-specific, therapeutic vaccines for cancer","volume":"18","author":"Hu","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.eclinm.2025.103378_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-0716-4542-0_1","article-title":"Current landscape of therapeutic cancer vaccines","volume":"2926","author":"Rosenthal","year":"2025","journal-title":"Methods Mol Biol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103378_bib52","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-025-01670-w","article-title":"Cancer vaccines: current status and future directions","volume":"18","author":"Zhou","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"15_suppl","key":"10.1016\/j.eclinm.2025.103378_bib53","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1200\/JCO.2019.37.15_suppl.2523","article-title":"A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors","volume":"37","author":"Burris","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025003104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025003104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:20:44Z","timestamp":1777634444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025003104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":52,"alternative-id":["S2589537025003104"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103378","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic anti-cancer vaccines: a systematic review of prospective intervention trials for common hematological malignancies","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103378","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103378"}}